Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03012100
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:50.720070+00:00
Published At
2023-01-13T00:00:00+00:00
Record Updated At
2023-01-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Bilateral Breast Carcinoma", "Breast Inflammatory Carcinoma", "Stage IB Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Triple-Negative Breast Carcinoma", "Unilateral Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-01-13"
protocolSection.identificationModule.nctId
"NCT03012100"
protocolSection.identificationModule.officialTitle
"Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Bilateral Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Breast Inflammatory Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IB Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage II Breast Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage IIA Breast Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage IIB Breast Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage III Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Breast Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Triple-Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Unilateral Breast Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.